Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OCTRU/CSM have recruited a new lead statistician to join the team.

Dr Iftekhar Khan has joined the CTU this week as Lead Statistician for our early phase and oncology trial portfolio. He joins us from King’s College, London, and prior to this he has worked in academia and industry over the last 15 years on clinical trials.

 

Dr Khan spoke to us about his interests and previous experience:

''I come with over 15 years experience in academia, industry and MHRA as a statistician. In previous jobs I have been head of Phase I at Eli LIlly, Merck and was responsible for Phase I trials at the UCL CRUK Cancer Trials Centre. I am also a senior statistical assessor within the licensing division of the MHRA. My interests lie in two areas at the extremes of the drug development spectrum: Phase I and Statistical Methods in Health Economics (I also happen to be a qualified health economist). I have written books on Design & Analysis of Clinical Trials for Economic Evaluation (Chapman & Hall; 2015); Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data (Chapman & Hall April 2019); and a forthcoming book on Sample Sizes For Clinical trial Trials Using Bayesian Methods (Chapman & Hall, due late 2019).

 I also like sailing, walking/trekking and playing cricket (when I can!).''

 

We look forward to expanding our portfolio of early phase trials with Dr Khan’s guidance.